Business Wire

Biocytogen Awarded U.S. Patent for RenLite ® Common Light Chain Mouse Platform

Share

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite® fully human common light chain mouse platform.

RenLite® mice, developed using Biocytogen’s proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCETM) technology, feature the in situ replacement of the entire human antibody heavy chain variable region genes and a single light chain variable region gene. This enables the generation of highly diverse fully human antibodies that share a common light chain, effectively avoiding light-heavy chain mismatches during the assembly of bispecific antibodies, thereby significantly reducing the complexity of the CMC process. The molecular structures of these bispecific antibodies resemble monoclonal antibodies, exhibiting favorable physicochemical properties. Leveraging RenLite® and RenLite® KO mice, Biocytogen has generated a library of antibodies targeting over 200 TAA targets, enabling the rapid development of bispecific antibody and bispecific antibody-drug-conjugate (ADC) therapies.

In addition to the RenLite® platform, Biocytogen’s independently developed RenMice® series includes RenMabTM, RenNano®, RenTCRTM and RenTCR-mimicTM platforms. These five fully human antibody/TCR mouse platforms cater to the diverse R&D needs of pharmaceutical companies globally. Since their debut in 2019, the RenMice® platforms have garnered widespread recognition within the biotech and pharmaceutical industries. As of December 31, 2023, Biocytogen has established 47 target-nominated RenMice® licensing projects with over 20 multinational corporations (MNCs) and biopharmaceutical/biotech companies, including Merck KGaA, Janssen, Xencor, BeiGene and Innovent. The RenMice® platform has generated a library of over 400,000 fully human antibodies against thousands of targets and high-quality candidate antibodies, facilitating 103 projects encompassing co-development, out-licensing, and transfer agreements.

The U.S. patent authorization for the RenLite® platform technology demonstrates Biocytogen’s exceptional innovation capabilities and global competitiveness. Biocytogen will continue to pursue global patent strategies and protect key technologies, offering advanced technology platforms and robust intellectual property protection for its partners. Besides the United States, patent applications for the RenLite® platform have been submitted in China, Europe, Japan, South Korea, Canada, Singapore, Russia, Israel, Australia, and other countries and regions with authorizations in progress.

About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice®, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240620000304/en/

Contacts

Biocytogen
Antibody assets and platforms: BD-Licensing@biocytogen.com
Press Contact: pr@bbctg.com.cn

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Citco Grows Asia Pacific Presence With New Japan Office12.11.2024 17:30:00 CET | Press Release

The Citco group of companies (Citco), the leading asset-servicer to the alternative investment sector, has announced the launch of Citco Japan Co KK. This new entity in Japan underscores Citco’s commitment to the Asia- Pacific region and bolsters its global offering to both current and prospective clients. Citco has over $2 trillion in assets under administration (AuA) and offers a full suite of middle-office and back-office services to alternative investment companies across the globe. These services include fund accounting, treasury and loan handling, investor services, corporate services, regulatory and risk reporting, banking solutions, and tax and financial reporting services, among others. Citco Japan Co KK is situated in Grantokyo South Tower 11F, 1-9-2 Marunouchi Chiyoda-Ku, Tokyo, 100-6611, Japan, and will operate as Citco’s local operational headquarters in the region. The team will offer fund accounting, fund operations and Special Purpose Vehicle (SPV) administration servic

Asymchem’s Fully Automated Peptide Production Lines Set New Benchmarks as Large-Scale Capacity Continues to Grow12.11.2024 17:00:00 CET | Press Release

To facilitate large-scale production of peptide drugs, Asymchem (stock codes: 002821.SZ/6821.HK), a leading global pharmaceutical contract development and manufacturing organization (CDMO), has achieved fully automated manufacturing. One initial hurdle was equipment scale-up. In particular, the optimal suspension and mixing of resin with reactants and the structural design of the synthesizer required careful attention. To address this, Asymchem’s Chemical Engineering Department (CED) utilized advanced simulation techniques and experimental validation to finalize the solid-phase synthesizer design and define the stirring paddles’ structural characteristics. The new structure is in the patent application process and is planned to be scaled up for use in 2000-liter solid-phase synthesizer equipment. The implementation of an automated formulation system was an additional challenge. Asymchem achieved this and additionally developed a host computer system that seamlessly interfaces with the

BST Global Launches AI + Data Impact Survey for the AEC Industry12.11.2024 16:41:00 CET | Press Release

BST Global, the leading provider of AI-powered project intelligence™ solutions for the AEC industry, has launched its groundbreaking AI + Data Survey globally. Seeking insights from technology and data leaders of architecture, engineering and environmental consultancies around the world, the survey will be available until 11:59 p.m. ET, December 13, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241112980057/en/ BST Global, the leading provider of AI-powered project intelligence™ solutions for the AEC industry, has launched its groundbreaking AI + Data Survey globally. Seeking insights from technology and data leaders of architecture, engineering and environmental consultancies around the world, the survey will be available until 11:59 p.m. ET, December 13, 2024. (Graphic: BST Global) BST Global partnered with BST Global’s AI + Data Consortium and the American Council of Engineering Companies' (ACEC) Technology Committ

Medidata and Bioforum Bolster Decade-Long Relationship to Advance Clinical Data and Biometric Solutions for Clinical Trials12.11.2024 16:40:00 CET | Press Release

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced a new enterprise agreement with Bioforum, a biometrics CRO that serves clinical trial sponsors worldwide. Building on more than a decade of collaboration, the expanded partnership provides Bioforum’s biotech customers with broader access to Medidata’s AI-powered technology, enabling a more agile clinical development experience. In addition to Medidata solutions such as Medidata Rave EDC and Medidata Rave RTSM, which Bioforum has leveraged to deliver 60 studies across a range of therapeutic areas, the CRO is adding Medidata Clinical Data Studio and Medidata eConsent to streamline data flow, maintain data integrity, and ensure compliance. “With our team of experts, industry-leading biometric services, and proprietary technology, Bioforum empowers sponsors to seamlessly manage their clinical data in one place and ensure it’s secure, accurate, and ready for an

ATRC’s VentureOne Launches QuantumGate to Secure Data for the Quantum Era at CyberQ12.11.2024 16:37:00 CET | Press Release

The Advanced Technology Research Council’s commercialization arm, VentureOne, has launched QuantumGate, a new venture that offers a suite of advanced data security products to protect organizations’ data assets in the quantum era, at CyberQ in Abu Dhabi today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241112430830/en/ ATRC’s VentureOne Launches QuantumGate to Secure Data for the Quantum Era at CyberQ (Photo: AETOSWire) H.E. Faisal Al Bannai, the Secretary General of ATRC, said, “The quantum era isn’t a distant threat—it is here. The launch of QuantumGate is a pivotal step in safeguarding invaluable data assets against ever-increasing cybersecurity threats. QuantumGate’s sovereign solutions will ensure our country’s and our organizations’ sensitive information stays safe.” “Cryptographic algorithms are used by virtually all organizations to encrypt and protect data,” said Dr. Najwa Aaraj, the CEO of the Technology Innova

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye